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Abstract
Introduction
Pneumonia is an important cause of morbidity and mortality in persons living with human
immunodeficiency virus (HIV) infection. How immune activation differs among HIV-infected
and HIV-uninfected adults with pneumonia is unknown.
Methods
The Inflammation, Aging, Microbes, and Obstructive Lung Disease (I AM OLD) Cohort is a
prospective cohort of adults with pneumonia in Uganda. In this cross-sectional analysis,
plasma was collected at pneumonia presentation to measure the following 12 biomarkers:
interleukin 6 (IL-6), soluble tumor necrosis factor receptors 1 and 2 (sTNFR-1 and sTNFR-
2), high sensitivity C-reactive protein (hsCRP), fibrinogen, D-dimer, soluble CD27 (sCD27),
interferon gamma-inducible protein 10 (IP-10), soluble CD14 (sCD14), soluble CD163
(sCD163), hyaluronan, and intestinal fatty acid binding protein. We asked whether bio-
marker levels differed between HIV-infected and HIV-uninfected participants, and whether
higher levels of these biomarkers were associated with mortality.
Results
One hundred seventy-three participants were enrolled. Fifty-three percent were HIV-
infected. Eight plasma biomarkers—sTNFR-1, sTNFR-2, hsCRP, D-dimer, sCD27, IP-10,
sCD14, and hyaluronan—were higher among participants with HIV infection, after
PLOS ONE | https://doi.org/10.1371/journal.pone.0216680 May 15, 2019 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Wang RJ, Moore J, Moisi D, Chang EG,
Byanyima P, Kaswabuli S, et al. (2019) HIV
infection is associated with elevated biomarkers of
immune activation in Ugandan adults with
pneumonia. PLoS ONE 14(5): e0216680. https://
doi.org/10.1371/journal.pone.0216680
Editor: Cristian Apetrei, University of Pittsburgh
Centre for Vaccine Research, UNITED STATES
Received: March 15, 2019
Accepted: April 8, 2019
Published: May 15, 2019
Copyright: © 2019 Wang et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The Makerere
University School of Medicine Research and Ethics
Committee has determined that, although the
minimal dataset has been de-identified, the
presence of sensitive information in the dataset,
including HIV status, requires that the data have
additional privacy protections. Individuals may
request access to the data by emailing Dr. Abdul
Sessolo, the contact person for the I AM OLD
Steering Committee, at asessolo@idrc-uganda.org.
Persons requesting the data must have appropriate
human subjects research training and approvals,
adjustment for pneumonia severity. Higher levels of 8 biomarkers—IL-6, sTNFR-1, sTNFR-
2, hsCRP, IP-10, sCD14, sCD163, and hyaluronan—were associated with increased 2-
month mortality.
Conclusions
As in other clinical contexts, HIV infection is associated with a greater degree of immune
activation among Ugandan adults with pneumonia. Some of these are also associated with
short-term mortality. Further study is needed to explore whether these biomarkers might
predict poor long-term outcomes—such as the development of obstructive lung disease—in
patients with HIV who have recovered from pneumonia.
Introduction
Although infections by opportunistic pathogens have declined with uptake of antiretroviral
therapy (ART), pneumonia remains an important cause of morbidity and mortality in persons
living with human immunodeficiency virus (HIV) infection. HIV-infected persons have a
higher risk of pneumonia compared to HIV-uninfected persons.[1–3] Among persons with
HIV infection, the occurrence of pneumonia is associated with increased risk of airway
obstruction,[4] lung cancer,[5] and death.[6]
Extensive prior research has documented that HIV infection is associated with abnormal
immune activation.[7] Biomarkers of inflammation,[8] interferon response,[9] T-cell activa-
tion,[10] and monocyte and macrophage activation[11,12] have been shown to be increased
among HIV-infected persons compared to uninfected persons, some of which persist even
after virologic suppression with ART. Furthermore, persistent immune activation in the
setting of ART-mediated viral suppression has been associated with several chronic
morbidities—including cardiovascular disease,[13] neurocognitive dysfunction,[14] and dia-
betes[15]—and mortality.[16–18]
HIV infection is also independently associated with chronic obstructive pulmonary disease
(COPD)[19] and, among HIV-infected persons, a history of pneumonia is an established risk
factor for airway obstruction.[4] It is unknown whether abnormal immune activation may
play a role in mediating a potential causal relationship between HIV infection, pneumonia,
and the development of COPD. To our knowledge, no prior study has investigated differences
in immune activation between HIV-infected and HIV-uninfected persons in the setting of
pneumonia.
To better understand the association between HIV infection and immune activation in the
setting of pneumonia, we conducted a cross-sectional study to compare markers of immune
activation between HIV-infected and HIV-uninfected Ugandan adults with pneumonia.
Twelve markers were selected to evaluate different aspects of immune activation: inflammation
(interleukin 6, soluble tumor necrosis factor receptor 1, soluble tumor necrosis factor receptor
2, and high sensitivity C-reactive protein), coagulation (fibrinogen and D-dimer), T-cell acti-
vation (soluble CD27), interferon response (interferon gamma-inducible protein 10), macro-
phage and monocyte activation (soluble CD14 and soluble CD163), fibrosis (hyaluronan), and
gut epithelial integrity (intestinal fatty acid binding protein). These biomarkers were selected
because they have previously been shown to be elevated or to be predictive of poor outcomes,
or both, among HIV-infected persons.[13–17,20–22] Our goals were to determine whether
biomarker levels differed between HIV-infected and HIV-uninfected participants with
HIV infection and biomarkers in pneumonia
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pneumonia, and whether higher levels of these biomarkers were associated with increased
2-month mortality.
Methods
Study design
This is a cross-sectional analysis of baseline characteristics of a cohort of adults with pneumo-
nia in Uganda.
Study population
The Inflammation, Aging, Microbes, and Obstructive Lung Disease (I AM OLD) Cohort is a
prospective cohort study of adults with pneumonia in Uganda. Adult patients 18 years or older
who presented with suspected pneumonia to the China-Uganda Friendship Hospital Naguru,
an urban district-level hospital in Kampala, Uganda, were screened for enrollment. Patients
were eligible for inclusion if they complained of cough and had an abnormal chest radiograph
determined by one of two pulmonologists (RL or WW) to be consistent with a pneumonia.
Patients were excluded if they were pregnant or unable to provide consent.
Measurements
Demographic, clinical, and laboratory data were collected using standardized case report
forms at the time of enrollment. Data that were collected included reported symptoms, vital
signs, and oxygen saturation by pulse oximetry. Functional status was ascertained by asking
participants what percentage of their day was spent in bed. Participants were categorized as
bedbound if they reported spending greater than 50 percent of their day in bed. If a participant
reported known HIV infection, data regarding ART and trimethoprim/sulfamethoxazole
Pneumocystis pneumonia prophylaxis were recorded, and a blood sample was collected for
CD4 count. If a participant reported unknown or negative HIV status, the participant was
offered HIV testing and, if positive, a blood sample was collected for CD4 count. Sputum was
obtained from all patients for testing for tuberculosis (TB) by smear microscopy, molecular
testing by GeneXpert MTB/RIF (Cepheid, Sunnyvale, California, United States), and mycobac-
terial culture with Lowenstein-Jensen and Mycobacterial Growth Indicator Tubes. HIV-
infected participants whose sputa were negative for acid-fast bacilli on smear microscopy and
negative for tuberculosis by GeneXpert MTB/RIF underwent bronchoscopy if clinically indi-
cated. During bronchoscopy, the tracheobronchial tree was inspected for lesions consistent
with Kaposi’s sarcoma, and bronchoalveolar lavage (BAL) samples were obtained. BAL sam-
ples were inspected by microscopy for Pneumocystis jirovecii using a modified Giemsa stain.
BAL samples were also tested for tuberculosis by smear microscopy and by mycobacterial cul-
ture with Lowenstein-Jensen and Mycobacterial Growth Indicator Tubes.
Blood samples for all participants were collected for biomarker measurement via peripheral
venipuncture, from which plasma was extracted and cryopreserved at -80˚C before being
shipped on dry ice to the United States. Twelve plasma biomarkers were selected for measure-
ment by immunoassay to assess for immune activation. As mentioned previously, the selected
biomarkers were: interleukin 6 (IL-6), soluble tumor necrosis factor receptor 1 (sTNFR-1), sol-
uble tumor necrosis factor receptor 2 (sTNFR-2), high sensitivity C-reactive protein (hsCRP),
fibrinogen, D-dimer, soluble CD27 (sCD27), interferon gamma-inducible protein 10 (IP-10,
also known as CXCL10), soluble CD14 (sCD14), soluble CD163 (sCD163), hyaluronan, and
intestinal fatty acid binding protein (IFABP). The biomarkers were measured using ELISA kits
obtained from R&D Systems (for IL-6, sTNFR-1, sTNFR-2, hsCRP, IP-10, sCD14, sCD163,
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hyaluronan, and IFABP), Diagnostica Stago (for D-dimer), and Abcam (for fibrinogen). Study
personnel who performed biomarker measurements were blinded to clinical information,
including HIV status.
Patients or their surrogates were contacted by phone two months after enrollment to ascer-
tain vital status.
Statistical analysis
All data were analyzed with STATA 15.1 (StataCorp, College Station, Texas, United States).
Baseline characteristics were compared between HIV-infected and HIV-uninfected partici-
pants using Fisher’s exact test for categorical variables and the Mann-Whitney U test for con-
tinuous variables.
The primary analytic goal was to compare biomarker levels between HIV-infected and
HIV-uninfected participants. Because the distributions of biomarkers did not meet assump-
tions of normality, the nonparametric Mann-Whitney U test was used for comparisons.
We then evaluated whether differences in biomarker levels were independent of severity of
pneumonia. To do so, 5 variables known to be associated with pneumonia severity were
selected for adjustment; these were age, heart rate, respiratory rate, oxygen saturation, and
whether or not a participant was, by self-report, bedbound.[23,24] Initially, to determine
whether differences in biomarker levels were independent of pneumonia severity, we fit a mul-
tiple linear regression model for each biomarker as a continuous outcome in which HIV status
(infected or uninfected) was the predictor of interest, and co-variates were age, heart rate,
respiratory rate, oxygen saturation, and bedbound status. However, regression diagnostics sug-
gested that for several biomarkers, model residuals were not normally distributed and that var-
iance differed substantially between the HIV-infected and HIV-uninfected subgroups. To
satisfy modelling assumptions, biomarker levels were log10-transformed, and log-linear models
were then fitted using the same predictors. The adjusted percentage difference between HIV-
infected and HIV-uninfected participants for each biomarker was calculated by exponentiating
the model coefficients for HIV status and then plotted graphically. The log10-transformed bio-
marker levels were then further transformed by dividing by the interquartile range (IQR), and
linear models were again constructed with the same predictor variables. Dividing by the IQR
effectively standardized each biomarker to its own range of test values, allowing for compari-
son of the relative strength of association between HIV infection and each biomarker. To test
whether pneumonia etiology might contribute to differences in biomarker levels, we con-
ducted a sensitivity analysis by generating models restricted only to participants with TB
infection.
We then evaluated whether biomarker levels were predictive of 2-month mortality. For
each biomarker measured, the cohort was divided into tertiles. A risk ratio was calculated to
compare the risk of mortality for participants with values in the highest tertile to the risk of
mortality for participants in the lower two tertiles.
Ethical issues
Ethical approval was obtained from the Makerere University School of Medicine Research and
Ethics Committee, the Uganda National Council for Science and Technology, and the Univer-
sity of California San Francisco Committee on Human Research. All study participants were
informed about the study by a nurse or a physician and provided written informed consent
before participation. Disease management was conducted by staff physicians at the China-
Uganda Friendship Hospital Naguru.
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Results
Characteristics of the study population
One hundred seventy-three participants were enrolled in the I AM OLD cohort between Octo-
ber 6, 2015 and July 20, 2017. Table 1 summarizes their baseline characteristics. Forty-five per-
cent of participants were women and the median age for all participants was 33 years. Overall,
91 (52.6%) participants were HIV-infected. Sixty-seven participants had a prior diagnosis of
HIV infection, 29 (43.2%) of whom were on combination anti-retroviral therapy at the time of
presentation. All other participants agreed to be tested for HIV infection; 24 additional partici-
pants were newly diagnosed with HIV infection and 82 were determined to be HIV negative.
Table 1. Baseline characteristics, by HIV status.
Variable, n (%) or median [IQR] HIV uninfected
n = 82
HIV infected
n = 91
p-value
HIV-related variables
New diagnosis of HIV 24 (26.4)
On ART 29 (31.9)
On PCP† prophylaxis 42 (46.2)
CD4 count (n = 90) 134 [56–327]
Newly diagnosed with HIV (n = 24) 139 [54–293]
Known HIV, on ART (n = 28) 127 [58–350]
Known HIV, not on ART (n = 38) 138 [57–252]
CD4 count < 200 (n = 90) 57 (63.3)
Demographics
Female 33 (40.2) 44 (48.4) 0.36
Age 31.7 [26.6–40.4] 33.8 [29.1–44.3] 0.02
Symptoms
Cough 82 (100.0) 91 (100.0) -
Fever 67 (81.7) 86 (94.5) 0.02
Weight loss 65 (79.3) 87 (95.6) 0.002
Sputum production 69 (84.2) 77 (84.6) 1
Shortness of breath 47 (57.3) 55 (60.4) 0.76
Chest pain 62 (75.6) 56 (61.5) 0.05
Spending > 50% of day in bed 10 (12.2) 26 (28.6) 0.009
Exposures
Current tobacco use 8 (9.8) 6 (6.7) 0.58
Current alcohol use 36 (43.9) 38 (41.8) 0.88
Received antibiotics previously 70 (85.4) 70 (76.9) 0.18
Baseline vital signs
Heart rate 100 [81–115] 108 [91–124] 0.008
Heart rate > 120 13 (15.9) 28 (30.8) 0.03
Respiratory rate 22 [20–24] 24 [20–28] 0.03
Respiratory rate > 30 6 (7.3) 18 (19.8) 0.04
Oxygen saturation 96 [94–97] 95 [92–97] 0.10
Oxygen saturation < 90% 6 (7.3) 16 (17.6) 0.07
Diagnosed with tuberculosis 48 (58.5) 52 (57.1) 0.88
Diagnosed with PCP† 2 (2.2)
Fisher’s Exact Test was used for categorical variables, and Mann-Whitney U Test was used for continuous variables.
† Pneumocystis pneumonia
https://doi.org/10.1371/journal.pone.0216680.t001
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Among the 91 participants with HIV infection, the median CD4 count was 134 cells/μL and
nearly two-thirds had a CD4 count less than 200 cells/μL.
Participants with HIV infection were older, more likely to report fever and weight loss, and
more likely to be bedbound. They also had higher heart rates and respiratory rates. Participants
with HIV infection were more likely to have an oxygen saturation below 90% while breathing
room air (17.6% compared to 7.3%, p = 0.07). One hundred (57.8%) of the 173 participants
were diagnosed with TB. There was no significant difference in the proportion of patients
diagnosed with TB among HIV-infected patients than among HIV-uninfected patients (57.1%
compared to 58.5%, p = 0.88). Among HIV-infected participants, only two were found to have
Pneumocystis pneumonia.
Comparison of biomarker levels between HIV-infected and HIV-
uninfected participants
Table 2 reports the median biomarker levels for participants with HIV infection and partici-
pants without HIV infection. Plasma levels of all biomarkers other than fibrinogen and IFABP
were significantly higher for HIV-infected participants than for HIV-uninfected participants;
the differences persisted for all biomarkers regardless of whether or not the HIV-infected par-
ticipants were on ART at the time of enrollment, except for sCD163. Levels of sCD163 were
significantly higher for HIV-infected participants on ART compared to HIV-uninfected par-
ticipants, but not for HIV-infected participants not on ART (S1 Table).
To test whether the relationships between HIV infection and plasma biomarkers were inde-
pendent of pneumonia severity, multiple linear regression models were fitted to adjust for vari-
ables that are known to be associated with pneumonia severity: age, heart rate, respiratory rate,
oxygen saturation, and bedbound status. After adjustment, HIV infection remained signifi-
cantly associated with higher plasma concentrations of sTNFR-1, sTNFR-2, hsCRP, D-dimer,
sCD27, IP-10, sCD14, and hyaluronan. Fig 1 illustrates the adjusted percentage difference in
mean biomarker levels comparing participants with HIV infection to participants without
HIV infection. For example, after adjustment for pneumonia severity, the plasma concentra-
tion of IP-10 was 79% higher in participants with HIV infection than in participants without
Table 2. Median biomarker measurements, by HIV status.
Biomarkers,
median [IQR]
HIV-uninfected HIV-infected p-value
IL-6 (pg/mL) 14.0 [3.1–34.4] 25.6 [8.7–56.5] 0.002
sTNFR-1 (ng/mL) 1.49 [1.04–2.06] 2.41 [1.62–3.64] <0.0001
sTNFR-2 (ng/mL) 3.81 [3.01–6.17] 6.67 [5.10–13.19] <0.0001
hsCRP (μg/mL) 20.1 [5.9–61.2] 59.5 [19.4–141.8] 0.0007
Fibrinogen (mg/mL) 6.25 [4.25–9.76] 7.77 [4.33–11.9] 0.22
D-dimer (ng/mL) 574 [317–1,504] 1,079 [576–2,300] 0.0001
sCD27 (U/mL) 37.6 [17.7–56.3] 55.3 [29.3–106.5] 0.0003
IP-10 (ng/mL) 0.51 [0.20–1.01] 1.14 [0.57–1.73] <0.0001
sCD14 (μg/mL) 2.24 [1.76–2.87] 3.64 [2.77–4.55] <0.0001
sCD163 (ng/mL) 776 [508–1,399] 1,014 [623–1,544] 0.03
Hyaluronan (ng/mL) 37.4 [22.7–60.2] 72.6 [35.9–147.4] <0.0001
IFABP (ng/mL) 0.94 [0.59–1.58] 0.82 [0.36–1.29] 0.18
Differences were tested by Mann-Whitney U Test.
https://doi.org/10.1371/journal.pone.0216680.t002
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HIV infection. Although HIV infection was significantly associated with higher plasma con-
centrations of IL-6 and sCD163 in the univariate analysis, these associations were attenuated
with adjustment and were no longer statistically significant. Differences in the plasma concen-
tration of fibrinogen and IFABP between HIV-infected and HIV-uninfected participants did
not meet statistical significance in either the univariate or multivariate analyses.
To allow for comparison of the strength of association between HIV infection and each
plasma biomarker, each log10-transformed biomarker was standardized by dividing by its own
IQR. Multiple linear regression models were again fitted to adjust for pneumonia severity, and
the coefficients of association between HIV infection and each biomarker are reported in
Table 3. After standardization for dynamic range of testing, HIV infection was most strongly
associated with sCD14, followed by sTNFR-2, hyaluronan, and IP-10.
To assess whether the association between HIV infection and elevated biomarkers would be
affected by pneumonia etiology, we conducted a sensitivity analysis in which we restricted the
IQR-standardized models only to participants diagnosed with tuberculosis which was the pre-
dominant pneumonia etiology in this cohort. When restricting analysis only to participants
diagnosed with tuberculosis, the associations of hsCRP and D-dimer with HIV infection were
attenuated and no longer significant; the other associations between HIV infection and bio-
marker levels were preserved (S2 Table).
Fig 1. Adjusted percentage difference in mean biomarker levels comparing HIV-infected participants with HIV-uninfected
participants. Each point represents the adjusted percentage difference in mean biomarker levels comparing participants with HIV
infection to participants without HIV infection, as estimated by log-linear regression models controlling for age, heart rate,
respiratory rate, oxygen saturation, and bedbound status. The bars represent the 95% confidence intervals for the estimate. In cases
when the bounds of the 95% confidence interval include 0, the points and bars have been shaded in gray. The graphic can be
interpreted as per this example: after adjustment for age, heart rate, respiratory rate, oxygen saturation, and bedbound status, the
plasma concentration of IP-10 was 79% higher in participants with HIV infection than in participants without HIV infection, with a
95% confidence interval of 33% to 141%.
https://doi.org/10.1371/journal.pone.0216680.g001
HIV infection and biomarkers in pneumonia
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Biomarkers and 2-month mortality
Of the 173 participants included in the analysis, 151 (87.2%) were alive at 2 months, 13 (7.5%)
had died, and 9 (5.2%) were lost to follow-up. Of the 13 participants who died, 9 were HIV-
infected and 4 were HIV-uninfected. Mortality for HIV-infected participants was higher than
for HIV-uninfected participants (9.9% compared to 4.9%, p = 0.25) but this difference was not
statistically significant. Of the 9 participants lost to follow-up, 8 were HIV-infected and 1 was
HIV-uninfected. HIV-infected participants were more likely to be lost to follow-up (8.8%
compared to 1.2%, p = 0.04). Biomarker levels were not significantly different when comparing
participants lost to follow-up with participants known to be alive at 2 months after enrollment
(S3 Table).
Biomarker association with mortality was compared for the 164 participants with known
2-month vital status. When comparing participants with biomarker levels in the highest tertile
to participants with biomarker levels in the lower two tertiles, higher levels of IL-6, sTNFR-1,
sTNFR-2, hsCRP, IP-10, sCD14, sCD163, and hyaluronan were significantly associated with
increased risk of mortality (Table 4). In a stratified analysis, we did not detect any effect modi-
fication by HIV status, although this study was not sufficiently powered to do so (S4 Table).
Discussion
We measured the levels of 12 biomarkers of immune activation in plasma samples obtained
from Ugandan adults with pneumonia, of whom 53% were HIV-infected and 58% were diag-
nosed with TB. We found that plasma concentrations of 10 of the 12 biomarkers were signifi-
cantly higher among participants with HIV infection, and that 8 of the 12 biomarkers
remained significantly higher even after adjustment for pneumonia severity. These 8 biomark-
ers were sTNFR-1, sTNFR-2, hsCRP, D-dimer, sCD27, IP-10, sCD14, and hyaluronan; of
these, sCD14, sTNFR-2, hyaluronan, and IP-10 were most strongly associated with HIV
infection.
The 8 biomarkers associated with HIV infection in this cohort reflect the activity of multiple
biologic pathways, including inflammation (sTNFR-1, sTNFR-2, hsCRP), coagulation (D-
dimer), T-cell activation (sCD27), interferon response (IP-10), monocyte and macrophage
activation (sCD14), and fibrosis (hyaluronan). Collectively, these data indicate that HIV infec-
tion is associated with a greater degree of immune activation even in the context of an acute
Table 3. Coefficient estimates for the effect of HIV status on log10-transformed plasma biomarker level divided by interquartile range, after adjustment for age,
heart rate, respiratory rate, oxygen status, and functional status with multiple linear regression modeling.
Biomarker Coefficient 95% confidence interval p-value
Interleukin 6 0.185 (-0.029, 0.398) 0.09
Soluble TNF Receptor 1 0.371 (0.178, 0.565) <0.001
Soluble TNF Receptor 2 0.594 (0.348, 0.840) <0.001
High sensitivity C-reactive protein 0.289 (0.122, 0.565) 0.04
Fibrinogen 0.155 (-0.211, 0.522) 0.40
D-dimer 0.303 (0.082, 0.524) 0.007
Soluble CD27 0.326 (0.093, 0.559) 0.007
IFN-γ-Inducible Protein 10 0.427 (0.209, 0.645) <0.001
Soluble CD14 0.712 (0.520, 0.904) <0.001
Soluble CD163 0.163 (-0.060, 0.386) 0.15
Hyaluronan 0.447 (0.235, 0.659) <0.001
Intestinal Fatty Acid Binding Protein -0.109 (-0.414, 0.197) 0.48
https://doi.org/10.1371/journal.pone.0216680.t003
HIV infection and biomarkers in pneumonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0216680 May 15, 2019 8 / 14
infection like pneumonia. This is consistent with previous research that has found that, in
other clinical contexts, plasma levels of these biomarkers are elevated in persons with HIV
infection compared to uninfected controls and that, even in the setting of treatment with ART,
abnormal immune activation persists in HIV-infected individuals.[8,9,25–29]
We also conducted an analysis of whether these plasma biomarkers were predictive of mor-
tality in a population of adults with pneumonia that is unique because of a high prevalence of
HIV and TB infection. We found that 8 of the 12 biomarkers were predictive of short-term
mortality after pneumonia. These were IL-6, sTNFR-1, sTNFR-2, hsCRP, IP-10, sCD14,
sCD163, and hyaluronan. To our knowledge, this is the first time that mortality after pneumo-
nia has been shown to be associated with sTNFR-1, sTNFR-2, sCD14, IP-10, and hyaluronan;
these may be candidate biomarkers for future studies to ascertain their predictive utility.
Our study has several important limitations. The cross-sectional study design limits our
ability to draw causal inferences. Specifically, the cross-sectional study design limits our ability
to implicate immune activation as a mediator of poor long-term outcomes, such as obstructive
lung disease, among HIV-infected patients who recover from pneumonia; longitudinal pro-
spective cohort studies may be instrumental to answering this question. Also, since plasma was
obtained at the time of clinical presentation, we cannot ascertain whether these biomarkers
were elevated prior to the onset of pneumonia—and perhaps may have had a role in the patho-
genesis of pneumonia—or whether these biomarkers reflect a differential host response to
pneumonia in the setting of HIV infection. There is evidence to support both explanations.
For example, in both HIV-infected and HIV-uninfected persons, higher levels of hsCRP were
predictive of increased risk for developing pneumonia.[30,31] On the other hand, several bio-
markers that were tested, such as IL-6 and hsCRP, are known to be part of the normal inflam-
matory response to an infection, such as pneumonia, and may be dysregulated in the setting of
HIV infection.[32,33] It seems likely that both explanations contribute to some degree to the
differences in biomarker levels observed in this study, but teasing apart the causal relationship
is beyond the capacity of a cross-sectional study.
A second limitation regards our ability to adjust completely for pneumonia severity. Analy-
sis of baseline characteristics indicates that, in general, participants with HIV infection likely
had more severe pneumonia, as evidenced by statistically significant differences in vital signs
Table 4. Risk ratios comparing the risk of mortality for the highest tertile compared to lower tertiles for each
biomarker.
Biomarker Risk Ratio 95% confidence interval p-value
High sensitivity C-reactive protein 6.13 (1.74, 21.6) 0.002
Soluble CD14 4.71 (1.52, 14.6) 0.005
Soluble TNF Receptor 1 4.71 (1.52, 14.6) 0.005
IFN-γ-Inducible Protein 10 4.34 (1.40, 13.5) 0.01
Interleukin 6 4.04 (1.27, 12.8) 0.02
Soluble TNF Receptor 2 3.44 (1.18, 10.0) 0.03
Hyaluronan 3.35 (1.15, 9.75) 0.03
Soluble CD163 3.29 (1.13, 9.57) 0.03
D-dimer 1.23 (0.42, 3.57) 0.76
Intestinal Fatty Acid Binding Protein 1.01 (0.32, 3.18) 1
Fibrinogen 0.98 (0.31, 3.08) 1
Soluble CD27 0.86 (0.23, 3.16) 1
Differences in risk of death were tested by Fisher’s Exact Test.
https://doi.org/10.1371/journal.pone.0216680.t004
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(heart rate and respiratory rate) and bedbound status. It is possible that differences in bio-
marker levels between participants with and without HIV infection might be at least partially
attributable to differences in disease severity that we were unable to measure and adjust for in
our analysis. Higher plasma levels of hsCRP and D-dimer have been shown to be associated
with mortality in patients with pneumonia.[34–40] Plasma hyaluronan has been shown to be
associated with mortality in patients with sepsis.[41–43] In our analysis, we attempted to adjust
for the severity of pneumonia, but our ability to do so is likely incomplete. However, we also
note the possibility that abnormal immune activation and an inflammatory milieu may medi-
ate the effect of HIV infection on pneumonia severity, in which case adjustment for disease
severity may not be appropriate and may in fact attenuate the true association between HIV
infection and plasma biomarker levels.
Thirdly, there was limited data obtained in this study regarding pneumonia etiology, other
than tuberculosis, and it is possible that differences in pneumonia etiology between HIV-
infected and HIV-uninfected participants may account for some degree of difference in bio-
marker levels. Specifically, opportunistic infections, such as Pneumocystis jirovecii are known
to elicit a strong host inflammatory response.[44,45] However, only two HIV-infected partici-
pants in this study were diagnosed with Pneumocystis pneumonia. Furthermore, a recent
cohort study in Malawi of a similar population of adult patients with pneumonia revealed that,
after tuberculosis, the most common etiology of pneumonia was Streptococcus pneumoniae,
followed by respiratory viruses, in both HIV-infected and HIV-uninfected patients.[46] There-
fore, the likelihood of substantial differences in pneumonia etiology between HIV-infected
and HIV-uninfected participants is small and we do not think that this possibility invalidates
our results.
A fourth limitation regards the validity of extending the conclusions of this study to other
populations. The high proportion (> 50%) of participants with TB is unique in this cohort,
and the findings of this study may not reflect the biology of other populations of adults with
pneumonia, in which the proportion of participants with TB may not be as high. Also, HIV-
infected participants in this cohort are notable for the relatively low uptake of ART and low
CD4 counts. While this is not unusual in sub-Saharan Africa—the median CD4 count in a
similar cohort of Malawian patients with pneumonia was 99, compared to 134 in this study
[46]—it is likely that the relationship between several of these biomarkers and HIV infection
may be attenuated in other HIV populations with a higher proportion of viral suppression;
indeed, HIV viral load has been shown to be associated with increased levels of IP-10 and
sTNFR-2.[47,48]
Despite these limitations, we believe that this study represents a substantial contribution to
the literature. While biomarkers of immune activation have been studied extensively amongst
HIV-infected persons, few studies have measured them amongst HIV-infected and HIV-unin-
fected persons with a concurrent acute infection, such as pneumonia. Our novel finding that
participants with HIV infection have a greater degree of immune activation, even in the setting
of a pneumonia, confirms and extends prior research on the persistence of immune activation
among HIV-infected persons, including those who are virally suppressed on ART.
In summary, we measured 12 plasma biomarkers of immune activation in a cohort of
Ugandan adults diagnosed with pneumonia, 53% of whom were infected with HIV and 58% of
whom had TB. Plasma levels for 8 of these biomarkers—sTNFR-1, sTNFR-2, hsCRP, D-dimer,
IP-10, sCD14, sCD27, and hyaluronan—were higher among participants with HIV infection
as compared to those without HIV infection, after adjustment for pneumonia severity. These
results suggest that, among adults with pneumonia, concurrent HIV infection is associated
with a greater degree of immune activation. Furthermore, higher levels of 8 biomarkers—IL-6,
sTNFR-1, sTNFR-2, hsCRP, IP-10, sCD14, sCD163, and hyaluronan—were associated with
HIV infection and biomarkers in pneumonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0216680 May 15, 2019 10 / 14
increased 2-month mortality. Further study is needed to explore whether these biomarkers
might predict poor long-term outcomes—such as the development of obstructive lung
disease—in patients with HIV who have recovered from pneumonia.
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